[A clinical efficacy and safety study on coronary heart disease and angina treatment with Puerarin Injection].
To observe the clinical efficacy and safety of Puerarin Injection treatment on angina pectoris. 388 patients with angina pectoris, enrolled to Tianjin Fourth Central Hospital during January 2009 and February 2011 were selected and randomly divided into treatment or control groups with 194 patients of each. Based on the conventional therapy program, one group was given Puerarin Injection as treatment group while, the other was given with Danshen Injection as control group. Clinical efficacy, the attack rate of angina pectoris, oxygen consumption, indices on electrocardiogram, haemorheology and other adverse reactions among the two groups were compared. The total efficacy of the treatment group (88.14%, 171/194) was significantly higher than the control group (61.86%, 120/194) and the difference was statistically significant (P < 0.05). During the treatment, no significant adverse events were noticed in both of the two groups of patients. The Puerarin Injection treatment program on angina pectoris seemed effective and safe.